托法替布与肿瘤坏死因子抑制剂在真实世界类风湿关节炎患者中的疗效比较:一项前瞻性观察性研究
该研究基于韩国一家学术转诊医院的生物制剂登记数据库,比较托法替布与肿瘤坏死因子抑制剂(TNFi)治疗类风湿关节炎12个月后的缓解率。意向性治疗分析显示两组缓解率无显著差异(18.0% vs 19.6%,P=0.640),多变量分析OR 1.204(95%CI 0.720-2.013)。在未使用过JAKi和bDMARD的亚组中,托法替布缓解率优于TNFi(OR 1.867,95%CI 1.033-3.377)。托法替布不良事件更多,但严重不良事件发生率相似。
要点
- 托法替布与TNFi治疗12个月缓解率无显著差异(18.0% vs 19.6%,P=0.640)
- 未使用过JAKi和bDMARD亚组中托法替布缓解率优于TNFi(OR 1.867,95%CI 1.033-3.377)
- 托法替布不良事件更多,但严重不良事件发生率与TNFi相似
核心结论
- 在真实世界环境中,托法替布组与TNFi组12个月缓解率无显著差异。
- 安全性方面,托法替布不良事件发生率高于TNFi,但严重不良事件发生率两组相当。
研究设计与样本
- 前瞻性观察性研究,使用韩国一家学术转诊医院的生物制剂DMARD和托法替布登记数据。
- 共纳入665例类风湿关节炎患者,其中托法替布组200例、TNFi组455例,随访至少12个月。
- 托法替布组96例(48.0%)和TNFi组409例(89.9%)为bDMARD初治。
- 主要结局为12个月后基于DAS28-ESR的缓解率,采用多变量logistic回归估计OR并校正潜在混杂因素。
主要发现
- 意向性治疗分析显示两组缓解率无显著差异(托法替布组18.0% vs TNFi组19.6%,P=0.640)。
- 多变量分析显示托法替布与TNFi缓解率相当(OR 1.204,95%CI 0.720-2.013)。
- 在JAKi和bDMARD初治亚组中,托法替布缓解率优于TNFi(OR 1.867,95%CI 1.033-3.377)。
- 托法替布不良事件更多,但严重不良事件发生率与TNFi相似。
关键数值与推荐
- 缓解定义基于DAS28-ESR。
- 意向性治疗分析:托法替布组缓解率18.0% vs TNFi组19.6%,P=0.640。
- 多变量分析OR 1.204(95%CI 0.720-2.013)。
- JAKi和bDMARD初治亚组OR 1.867(95%CI 1.033-3.377)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to assess the effectiveness of tofacitinib vs TNF inhibitors (TNFis) in Korean patients with RA. METHODS: The study used data from a single academic referral hospital's registries of biologic DMARDs (bDMARDs) and tofacitinib and examined remission rates based on the DAS28-ESR after 12 months. Multivariable logistic regression analysis was used to estimate the odds ratio (OR) for achieving remission with tofacitinib compared with TNFi, adjusting for potential confounders. RESULTS: This analysis included 665 patients (200 on tofacitinib and 455 on TNFis) who were followed up for at least 12 months. Of these, 96 patients in the tofacitinib group (48.0%) and 409 patients in the TNFi group (89.9%) were treatment-naïve to bDMARDs. Intention-to-treat analysis revealed no significant difference in the remission rates between the two groups (18.0% vs 19.6%, P = 0.640). Multivariable analysis demonstrated comparable remission rates with tofacitinib and TNFi (OR 1.204, 95% CI 0.720-2.013). In the subpopulation naïve to Janus kinase inhibitors (JAKis) and bDMARDs, tofacitinib showed better remission rates than TNFis (OR 1.867, 95% CI 1.033-3.377). Tofacitinib had more adverse events but similar rates of serious adverse events to TNFis. CONCLUSION: In real-world settings, there was no significant difference in remission rates at 12 months between the tofacitinib and TNFi groups. In terms of safety, tofacitinib exhibited a higher incidence of adverse events compared with TNFis, while the occurrence of serious adverse events was comparable between the groups. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02602704.
引用
- Cho SK, Song YJ, Kim HW, et al. Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in patients with rheumatoid arthritis in real-world practice: a prospective observational study. Rheumatology (Oxford). 2025. PMID: 38366621. doi:10.1093/rheumatology/keae109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。